(PRRT) of Gastro-Entero-Pancreatic NeuroEndocrine Tumors

More documents

Recommendations

Info

<strong>PRRT</strong> with radiolabelled somatostatin analogues Subacute and Longterm (< 6.5 yrs) Side effects • Temporary hairloss, no baldness (grd I) • No effect on pituitary function • No important effect on thyroid function • Common: mild bone marrow suppression • Common: Lymphocytopenia • Rare: MDS, Leukemia (< 800 mCi) (3*) • No Kidney failure with AA protection • Rare: Liver toxicity (2*) • Temporary impaired spermatogenesis • Hormonal crises, need for special care 1 %
[ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate Therapy: A Patient with a <strong>Pancreatic</strong> NE Tumor OctreoScan Pre Therapy May 2001 Lu-octreotate Therapy 1 Oct 2001 Lu-octreotate Therapy 2 Dec 2001 Lu-octreotate Therapy 3 Feb 2002 OctreoScan Post Therapy Aug 2002 • The patient had PR (small lesions on CT and SPECT Octreoscan) and was progression free until July 2003 (2 yr) • Note the higher tumor uptake on the first octreotate scan compared to the OctreoScan • Note the decrease in tumor uptake after each treatment cycle
Page 1 and 2: Molecular Medicine Same Molecule/Ta
Page 3: Targeted Radionuclide Therapy with
Page 7 and 8: Molecular Medicine of GEPNET Introd
Page 9 and 10: Cytoreductive therapies for inopera
Page 11 and 12: Structure of a Radiopeptide Recepto
Page 13 and 14: Molecular Imaging at ErasmusMC
Page 15 and 16: Molecular Medicine at ErasmusMC
Page 17: [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate
Page 21 and 22: [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate
Page 27 and 28: PRRT with LuTate in GEPNET shows an
Page 31 and 32: Future Developments for PRRT in GEP
Page 33 and 34: Radiolabelled [DOTA 0 ,Tyr 3 ]Octre
Page 35 and 36: Proof of Concept in Prostate Cancer

(PRRT) of Gastro-Entero-Pancreatic NeuroEndocrine Tumors

Create successful ePaper yourself

Delete template?

Save as template?